biotech / news / / Times of India
The treatment, Lormalzi (donanemab) is among the first- of- its-kind to target amyloid plaques in the brain.
Eli Lilly has launched its Alzheimer's drug Lormalzi (donanemab) in India.
KEY POINTS
- Lormalzi targets amyloid plaques in the brain, shifting treatment beyond just cognitive symptom relief.
- The drug costs nearly Rs 92,000 per 350 mg vial and is administered intravenously every four weeks.
- Lormalzi received marketing authorisation for Alzheimer’s with mild cognitive impairment or early dementia.
- A Phase IV trial will be held in India to gather local safety and efficacy data.
COMPANIES
Summarized by Newsio from Times of India. How we summarize →